Bank of America downgraded shares of Integra Lifesciences (NASDAQ:IART) from a buy rating to a neutral rating in a research report released on Tuesday morning, Marketbeat Ratings reports.
A number of other equities analysts have also weighed in on the company. Zacks Investment Research upgraded Integra Lifesciences from a sell rating to a hold rating in a research note on Tuesday, December 26th. Oppenheimer set a $58.00 price objective on Integra Lifesciences and gave the company a buy rating in a research note on Tuesday, December 12th. Royal Bank of Canada reiterated a sector perform rating and set a $50.00 price objective (up previously from $48.00) on shares of Integra Lifesciences in a research note on Thursday, November 9th. UBS Group reiterated a buy rating and set a $57.00 price objective on shares of Integra Lifesciences in a research note on Tuesday, October 31st. Finally, Wells Fargo & Co lowered Integra Lifesciences from an outperform rating to a market perform rating in a research note on Sunday, October 29th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $53.64.
Integra Lifesciences (IART) opened at $46.55 on Tuesday. The firm has a market capitalization of $3,670.00, a PE ratio of 76.31, a price-to-earnings-growth ratio of 1.56 and a beta of 0.65. Integra Lifesciences has a 52 week low of $40.51 and a 52 week high of $56.42. The company has a debt-to-equity ratio of 1.26, a quick ratio of 3.39 and a current ratio of 4.49.
In other news, VP Richard D. Gorelick sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total transaction of $70,785.00. Following the sale, the vice president now directly owns 21,665 shares in the company, valued at approximately $1,022,371.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Barbara B. Hill bought 10,768 shares of the company’s stock in a transaction dated Tuesday, October 31st. The shares were acquired at an average price of $46.66 per share, for a total transaction of $502,434.88. Following the completion of the transaction, the director now directly owns 55,540 shares in the company, valued at $2,591,496.40. The disclosure for this purchase can be found here. 21.50% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of IART. Capital Research Global Investors boosted its holdings in Integra Lifesciences by 227.0% in the 2nd quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock worth $212,441,000 after buying an additional 2,705,488 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Integra Lifesciences in the 2nd quarter worth about $112,068,000. Koch Industries Inc. boosted its holdings in Integra Lifesciences by 12,623.4% in the 2nd quarter. Koch Industries Inc. now owns 754,880 shares of the life sciences company’s stock worth $741,000 after buying an additional 748,947 shares during the last quarter. Orbimed Advisors LLC boosted its holdings in Integra Lifesciences by 155.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock worth $55,069,000 after buying an additional 664,000 shares during the last quarter. Finally, FMR LLC boosted its holdings in Integra Lifesciences by 6.2% in the 2nd quarter. FMR LLC now owns 8,084,562 shares of the life sciences company’s stock worth $440,690,000 after buying an additional 468,678 shares during the last quarter. Hedge funds and other institutional investors own 87.58% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Integra Lifesciences (IART) Stock Rating Lowered by Bank of America” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3128031/integra-lifesciences-iart-stock-rating-lowered-by-bank-of-america.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.